213 related articles for article (PubMed ID: 32801705)
1. Fatty Acid Synthase (FASN) siRNA-Encapsulated-Her-2 Targeted Fab'-Immunoliposomes for Gene Silencing in Breast Cancer Cells.
Khan A; Aljarbou AN; Aldebasi YH; Allemailem KS; Alsahli MA; Khan S; Alruwetei AM; Khan MA
Int J Nanomedicine; 2020; 15():5575-5589. PubMed ID: 32801705
[TBL] [Abstract][Full Text] [Related]
2. Her-2-directed systemic delivery of fatty acid synthase (FASN) siRNA with novel liposomal carrier systems in the breast cancer mouse model.
Khan A; Aljarbou AN; Khan S; Khan MA
J Drug Target; 2022 Jul; 30(6):634-645. PubMed ID: 35112640
[TBL] [Abstract][Full Text] [Related]
3. Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing.
Gao J; Sun J; Li H; Liu W; Zhang Y; Li B; Qian W; Wang H; Chen J; Guo Y
Biomaterials; 2010 Mar; 31(9):2655-64. PubMed ID: 20035999
[TBL] [Abstract][Full Text] [Related]
4. Comparison of anti-EGFR-Fab' conjugated immunoliposomes modified with two different conjugation linkers for siRNa delivery in SMMC-7721 cells.
Deng L; Zhang Y; Ma L; Jing X; Ke X; Lian J; Zhao Q; Yan B; Zhang J; Yao J; Chen J
Int J Nanomedicine; 2013; 8():3271-83. PubMed ID: 24023515
[TBL] [Abstract][Full Text] [Related]
5. Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes.
Gao J; Zhong W; He J; Li H; Zhang H; Zhou G; Li B; Lu Y; Zou H; Kou G; Zhang D; Wang H; Guo Y; Zhong Y
Int J Pharm; 2009 Jun; 374(1-2):145-52. PubMed ID: 19446771
[TBL] [Abstract][Full Text] [Related]
6. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
[TBL] [Abstract][Full Text] [Related]
7. Construction and evaluation of pH-sensitive immunoliposomes for enhanced delivery of anticancer drug to ErbB2 over-expressing breast cancer cells.
Li T; Amari T; Semba K; Yamamoto T; Takeoka S
Nanomedicine; 2017 Apr; 13(3):1219-1227. PubMed ID: 27965166
[TBL] [Abstract][Full Text] [Related]
8. siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes.
Hattori Y; Nakamura A; Arai S; Kawano K; Maitani Y; Yonemochi E
J Liposome Res; 2015; 25(4):279-86. PubMed ID: 25543847
[TBL] [Abstract][Full Text] [Related]
9. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
[TBL] [Abstract][Full Text] [Related]
10. Anti-neuropilin 1 antibody Fab' fragment conjugated liposomal docetaxel for active targeting of tumours.
Manjappa AS; Goel PN; Gude RP; Ramachandra Murthy RS
J Drug Target; 2014 Sep; 22(8):698-711. PubMed ID: 24766186
[TBL] [Abstract][Full Text] [Related]
11. PEGylated DC-Chol/DOPE cationic liposomes containing KSP siRNA as a systemic siRNA delivery Carrier for ovarian cancer therapy.
Lee J; Ahn HJ
Biochem Biophys Res Commun; 2018 Sep; 503(3):1716-1722. PubMed ID: 30049442
[TBL] [Abstract][Full Text] [Related]
12. Enhanced gene delivery to HER-2-overexpressing breast cancer cells by modified immunolipoplexes conjugated with the anti-HER-2 antibody.
Lee CH; Hsiao M; Tseng YL; Chang FH
J Biomed Sci; 2003; 10(3):337-44. PubMed ID: 12711861
[TBL] [Abstract][Full Text] [Related]
13. Quantitative silencing of EGFP reporter gene by self-assembled siRNA lipoplexes of LinOS and cholesterol.
Metwally AA; Blagbrough IS; Mantell JM
Mol Pharm; 2012 Nov; 9(11):3384-95. PubMed ID: 23057412
[TBL] [Abstract][Full Text] [Related]
14. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW
Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648
[TBL] [Abstract][Full Text] [Related]
15. Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer.
Corominas-Faja B; Vellon L; Cuyàs E; Buxó M; Martin-Castillo B; Serra D; García J; Lupu R; Menendez JA
Histol Histopathol; 2017 Jul; 32(7):687-698. PubMed ID: 27714708
[TBL] [Abstract][Full Text] [Related]
16. Targeting Her-2+ breast cancer cells with bleomycin immunoliposomes linked to LLO.
Kullberg M; Mann K; Anchordoquy TJ
Mol Pharm; 2012 Jul; 9(7):2000-8. PubMed ID: 22621404
[TBL] [Abstract][Full Text] [Related]
17. Multifunctional peptide-lipid nanocomplexes for efficient targeted delivery of DNA and siRNA into breast cancer cells.
Wan Y; Dai W; Nevagi RJ; Toth I; Moyle PM
Acta Biomater; 2017 Sep; 59():257-268. PubMed ID: 28655658
[TBL] [Abstract][Full Text] [Related]
18. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.
Jin Q; Yuan LX; Boulbes D; Baek JM; Wang YN; Gomez-Cabello D; Hawke DH; Yeung SC; Lee MH; Hortobagyi GN; Hung MC; Esteva FJ
Breast Cancer Res; 2010; 12(6):R96. PubMed ID: 21080941
[TBL] [Abstract][Full Text] [Related]
19. Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer.
Menendez JA; Mehmi I; Papadimitropoulou A; Vander Steen T; Cuyàs E; Verdura S; Espinoza I; Vellon L; Atlas E; Lupu R
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081219
[TBL] [Abstract][Full Text] [Related]
20. Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcome.
Yoshii Y; Furukawa T; Oyama N; Hasegawa Y; Kiyono Y; Nishii R; Waki A; Tsuji AB; Sogawa C; Wakizaka H; Fukumura T; Yoshii H; Fujibayashi Y; Lewis JS; Saga T
PLoS One; 2013; 8(5):e64570. PubMed ID: 23741342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
